Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489513 | 1.00 | BRD4 (1.00) | BRD4BAZ2A | |
| SCHEMBL16489503 | 0.90 | BRD4 (1.00) | BRD4BAZ2A | |
| SCHEMBL30298708 | 0.85 | BRD4 (1.00) | BRD4 | |
| SCHEMBL21401575 | 0.85 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489493 | 0.85 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489490 | 0.84 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489485 | 0.84 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489510 | 0.81 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489492 | 0.81 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489500 | 0.80 | BRD4 (1.00) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| WO-2019145410-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| WO-2015022332-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BRD4, MCL1, BET1 | BRD4 1/4885BAZ2A 54/4885 |
| US-20150051208-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BRD4 1346/4885BAZ2A 3446/4885 |
| US-20150246919-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BRD4 1346/4885BAZ2A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.